PRINCETON, N.J., Oct. 13, 2017 /PRNewswire/ -- Promius Pharma LLC announced today that it is presenting 9 posters at the Fall Clinical Dermatology Conference® in Las Vegas, NV, October 12-15, 2017.
The posters represent Promius Pharma's ongoing commitment to dermatological science. "Promius Pharma's forward-looking approach is a critical investment in the future of medical dermatology research," said Dr Mark Lebwohl of Icahn School of Medicine at Mount Sinai. "Findings from these studies will enable us to better understand a number of disease states and devise new strategies to provide relief."
Posters include findings for the disease states of acne, psoriasis, and head lice.
About Promius Pharma LLC
Promius Pharma is a wholly owned subsidiary of Dr. Reddy's Laboratories, one of the largest and most respected pharmaceutical companies in the world. With a robust commercial infrastructure and extensive research and development capabilities through its parent company, Promius Pharma is committed to bringing new products to market that meet patients' needs in dermatology and neurology. For more information, visit www.promiuspharma.com.
Promius Pharma, LLC
107 College Rd E
Princeton, NJ 08540
+1 (609) 375-6145
Lori McCreary (USA)
+1 (609) 375-2995
Copyright 2017 Promius Pharma, LLC
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation , including related integration issues. The company assumes no obligation to update any information contained herein.
SOURCE Promius Pharma LLC